Clinical impact of antibiotic resistance in respiratory tract infections

International Journal of Antimicrobial Agents

Volumn 29, Issue SUPPL. 1, 2007, Pages S6-

  Klugman, Keith P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Macrolides; Respiratory tract infection; Streptococcus pneumoniae; Telithromycin

Indexed keywords

AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; SULFAMETHOXAZOLE; TELITHROMYCIN; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DRUG RESISTANCE; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK FACTOR; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 33847338839     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(07)70004-3     Document Type: Article

References (33)

1. Jacobs M. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 117 Suppl 3A (2004) 3S-15S
2. File Jr. T., Garau J., Blasi F., et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125 (2004) 1888-1901
3. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 50 Suppl S1 (2002) 1-7
4. Feikin D., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 90 (2000) 223-229
5. Klugman K., Low D., Metlay J., Pechere J., and Weiss K. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int J Antimicrob Agents 24 (2004) 411-422
6. Farrell D., Canton R., and Hryniewicz W. Trends in antibacterial resistance of Streptococcus pneumoniae: PROTEKT global years 1-5. Clin Microbiol Infect 12 Suppl 4 (2006) P1279
7. Schito G., Farrell D., and Ramirez J. Activity of telithromycin against Streptococcus pneumoniae isolates resistant to other antibacterials: PROTEKT year 5. Clin Microbiol Infect 12 Suppl 4 (2006) P1280
8. Espinal M., Kim S., Suarez P., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283 (2000) 2537-2545
9. Paris M., Ramilo O., and McCracken Jr. G. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 39 (1995) 2171-2175
10. McMaster P., McIntyre P., Gilmour R., Gilbert L., Kakakios A., and Mellis C. The emergence of resistant pneumococcal meningitis - implications for empiric therapy. Arch Dis Child 87 (2002) 207-210
11. Varma J., Molbak K., Barrett T., et al. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis 191 (2005) 554-561
12. Kopp B., Nix D., and Armstrong E. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 38 (2004) 1377-1382
13. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?. J Chemother 11 Suppl 1 (1999) 35-43
14. Schrag S., Pena C., Fernandez J., et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286 (2001) 49-56
15. Baquero F., Baquero-Artigao G., Canton R., and Garcia-Rey C. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother 50 Suppl S2 (2002) 27-37
16. Vanderkooi O., Low D., Green K., Powis J., and McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 40 (2005) 1288-1297
17. Corso A., Severina E., Petruk V., Mauriz Y., and Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 4 (1998) 325-337
18. Richter S., Heilmann K., Coffman S., et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 34 (2002) 330-339
19. Klugman K. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 36 Suppl (2002) 3S-8S
20. Metlay J., Hofmann J., Cetron M., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30 (2000) 520-528
21. Yu V., Chiou C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37 (2003) 230-237
22. Klugman K., and Yu V. No impact of penicillin resistance on mortality. Clin Infect Dis 43 (2006) 261
23. Peterson L. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?. Clin Infect Dis 42 (2006) 224-233 robial Agents 29 Suppl. 1 (2007) S6-S10
24. Farrell D., Jenkins S., Brown S., Patel M., Lavin B., and Klugman K. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef (A) resistance. Emerg Infect Dis 11 (2005) 851-858
25. Klugman K., and Lonks J. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 11 (2005) 802-807
26. Daneman N., McGeer A., Green K., and Low D. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 43 (2006) 432-438
27. Fuller J., McGeer A., and Low D. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis 24 (2005) 780-788
28. Dias R., and Canica M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14. J Antimicrob Chemother 54 (2004) 1035-1039
29. Anon, Jacobs M., Poole M., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 130 (2004) 1-45
30. Bergman M., Huikko S., Huovinen P., Paakkari P., and Seppala H. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 50 (2006) 3646-3650
31. Stratton C. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 9 (2003) 10-16
32. Douthwaite S., Hansen L., and Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 36 (2000) 183-193
33. Poehlsgaard J., and Douthwaite S. The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord 2 (2002) 67-78